H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 26.44 HKD -1.2%
Market Cap: 23.1B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one HUTCHMED (China) Ltd stock under the Base Case scenario is 22.8 HKD. Compared to the current market price of 26.44 HKD, HUTCHMED (China) Ltd is Overvalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
22.8 HKD
Overvaluation 14%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

4.9
P/S
P/S
Price to Sales
4.9
vs History
50
vs Industry
29
Median 3Y
4.6
Median 5Y
5
Industry
2.7
Forward
4.6
More Details
6.4
P/E
P/E
Price to Earnings
6.4
vs History
24
vs Industry
13
Median 3Y
-6.3
Median 5Y
-8.7
Industry
22.1
Forward
35.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
26
Median 3Y
-6.9
Median 5Y
-9.9
Industry
17.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
26
Median 3Y
-8.5
Median 5Y
-12.8
Industry
23.3
More Details
2.4
P/B
P/B
Price to Book Value
2.4
vs History
86
vs Industry
21
Median 3Y
3.7
Median 5Y
3.8
Industry
2.3
More Details
2.8
EV/S
EV/S
Enterprise Value to Sales
2.8
vs History
66
vs Industry
38
Median 3Y
3
Median 5Y
3.5
Industry
2.8
Forward
2.7
More Details
6.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.4
vs History
62
vs Industry
28
Median 3Y
6.7
Median 5Y
8.8
Industry
5.6
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
3
Median 3Y
-20.2
Median 5Y
-16.5
Industry
13.3
Forward
103.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
2
Median 3Y
-18.6
Median 5Y
-16.1
Industry
16.6
Forward
116.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
33
Median 3Y
-3.2
Median 5Y
-6.3
Industry
15.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
24
Median 3Y
-6.7
Median 5Y
-9
Industry
17.6
More Details
4.6
EV/IC
EV/IC
Enterprise Value to IC
4.6
vs History
67
vs Industry
17
Median 3Y
5.1
Median 5Y
5.5
Industry
2
More Details

Multiples Across Competitors

Competitors Multiples
HUTCHMED (China) Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
HUTCHMED (China) Ltd
HKEX:13
23.1B HKD 4.9 6.4 -226.5 -86.1
US
Eli Lilly and Co
NYSE:LLY
717.8B USD 13.5 52 30.8 33.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
420.9B USD 4.6 18.6 14.1 18.6
CH
Roche Holding AG
SIX:ROG
214.8B CHF 3.6 26 9.7 11.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.5 15.3 11.1 12.4
UK
AstraZeneca PLC
LSE:AZN
178.3B GBP 4.3 29.1 113.5 169.7
CH
Novartis AG
SIX:NOVN
190B CHF 4.4 17.6 10.6 14
US
Merck & Co Inc
NYSE:MRK
203.1B USD 3.2 12.4 8 9.5
IE
Endo International PLC
LSE:0Y5F
197.4B USD 85.1 -67.5 313.3 785.7
US
Pfizer Inc
NYSE:PFE
138.1B USD 2.2 12.8 7.3 10
P/E Multiple
Earnings Growth PEG
HK
H
HUTCHMED (China) Ltd
HKEX:13
Average P/E: 21.1
6.4
-12%
N/A
US
Eli Lilly and Co
NYSE:LLY
52
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.6
28%
0.7
CH
Roche Holding AG
SIX:ROG
26
29%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
29.1
37%
0.8
CH
Novartis AG
SIX:NOVN
17.6
18%
1
US
Merck & Co Inc
NYSE:MRK
12.4
16%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -67.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
12.8
30%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
H
HUTCHMED (China) Ltd
HKEX:13
Average EV/EBITDA: 436.5
Negative Multiple: -226.5 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.8
30%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.1
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
13%
0.9
UK
AstraZeneca PLC
LSE:AZN
113.5
10%
11.3
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
US
Merck & Co Inc
NYSE:MRK
8
7%
1.1
IE
E
Endo International PLC
LSE:0Y5F
313.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
H
HUTCHMED (China) Ltd
HKEX:13
Average EV/EBIT: 1 876.7
Negative Multiple: -86.1 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.4
34%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
18.6
14%
1.3
CH
Roche Holding AG
SIX:ROG
11.4
5%
2.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.4
7%
1.8
UK
AstraZeneca PLC
LSE:AZN
169.7
22%
7.7
CH
Novartis AG
SIX:NOVN
14
11%
1.3
US
Merck & Co Inc
NYSE:MRK
9.5
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
785.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
10
10%
1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 284,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.